SCHEMBL25013643

SCHEMBL25013643

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(C(=O)N4CCN(CC)CC4)ccc3OCC)nc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 19/20 0.75
PDE6C P51160 3/20 0.75
HDAC1 Q13547 11/20 0.65
HDAC6 Q9UBN7 11/20 0.65
HDAC2 Q92769 7/20 0.65
PDE3B Q13370 3/20 0.65
PDE3A Q14432 3/20 0.65
HDAC3 O15379 1/20 0.64
NCOR2 Q9Y618 1/20 0.64
KMT2A Q03164 2/20 0.62
PDE1A P54750 2/20 0.62
PDE1B Q01064 2/20 0.62
PDE1C Q14123 2/20 0.62
MEN1 O00255 1/20 0.62
ALDH1A1 P00352 1/20 0.62
HPGD P15428 1/20 0.62
PDE2A O00408 1/20 0.61
ABCC4 O15439 1/20 0.61
ABCC5 O15440 1/20 0.61
PDE6D O43924 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174347 1.00 PDE5A (0.75) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL28476705 0.94 PDE5A (0.72) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL29707546 0.94 PDE5A (0.77) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL145682 0.94 PDE5A (0.77) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL28416630 0.91 PDE5A (0.76) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL29357402 0.91 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL2693448 0.91 PDE5A (0.85) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL7920627 0.87 PDE5A (0.82) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL28417929 0.87 PDE5A (0.82) PDE5APDE6CHDAC1HDAC6HDAC2
SCHEMBL7961020 0.86 PDE5A (1.00) PDE5APDE6CHDAC1HDAC6HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111732593-A Piperazine oxide derivative and composition, preparation method and application thereof 黄泳华 2020-10-02 CN claimed
CN-111297868-A Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases 黄泳华 2020-06-19 CN claimed
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION BEHAVIORAL DIAGNOSTICS, LLC (US) 2023-02-09 US disclosed
CN-111732593-A Piperazine oxide derivative and composition, preparation method and application thereof 黄泳华 2020-10-02 CN disclosed
CN-111297868-A Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases 黄泳华 2020-06-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION PDE5A, PDE3A, PDE2A PDE5A 1/4885PDE6C 15/4885HDAC1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.